Hadasit Bio - Asset Resilience Ratio

Latest as of June 2023: 57.00%

Hadasit Bio (HDST) has an Asset Resilience Ratio of 57.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read HDST liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

ILA8.36 Million
≈ $22.42K USD Cash + Short-term Investments

Total Assets

ILA14.67 Million
≈ $39.33K USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2008–2022)

This chart shows how Hadasit Bio's Asset Resilience Ratio has changed over time. See Hadasit Bio book value and equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hadasit Bio's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hadasit Bio (HDST) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ILA0.00 0%
Short-term Investments ILA8.36 Million 57.0%
Total Liquid Assets ILA8.36 Million 57.00%

Asset Resilience Insights

  • Very High Liquidity: Hadasit Bio maintains exceptional liquid asset reserves at 57.00% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Hadasit Bio Industry Peers by Asset Resilience Ratio

Compare Hadasit Bio's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Peptron Inc
KQ:087010
Biotechnology & Medical Research 57.41%
Pluristem
TA:PSTI
Biotechnology & Medical Research 48.26%
Purple Biotech Ltd
TA:KTOV
Biotechnology & Medical Research 0.01%
Bioneer Corporation
KQ:064550
Biotechnology & Medical Research 14.92%
MEDIPOST Co. Ltd
KQ:078160
Biotechnology & Medical Research 0.72%
Macrogen Inc
KQ:038290
Biotechnology & Medical Research 3.56%
Cell Biotech Co. Ltd
KQ:049960
Biotechnology & Medical Research 54.84%
Panagene Inc
KQ:046210
Biotechnology & Medical Research 0.14%

Annual Asset Resilience Ratio for Hadasit Bio (2008–2022)

The table below shows the annual Asset Resilience Ratio data for Hadasit Bio.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 38.65% ILA15.06 Million
≈ $40.36K
ILA38.95 Million
≈ $104.43K
+6.56pp
2021-12-31 32.09% ILA21.32 Million
≈ $57.14K
ILA66.41 Million
≈ $178.05K
-47.03pp
2020-12-31 79.12% ILA32.74 Million
≈ $87.77K
ILA41.38 Million
≈ $110.94K
+65.75pp
2019-12-31 13.37% ILA1.26 Million
≈ $3.37K
ILA9.41 Million
≈ $25.23K
+8.70pp
2018-12-31 4.67% ILA1.65 Million
≈ $4.42K
ILA35.34 Million
≈ $94.73K
-47.15pp
2017-12-31 51.82% ILA35.55 Million
≈ $95.30K
ILA68.60 Million
≈ $183.91K
+0.51pp
2016-12-31 51.31% ILA35.64 Million
≈ $95.54K
ILA69.46 Million
≈ $186.21K
+49.02pp
2015-12-31 2.28% ILA1.57 Million
≈ $4.20K
ILA68.61 Million
≈ $183.94K
-14.22pp
2014-12-31 16.50% ILA5.35 Million
≈ $14.34K
ILA32.42 Million
≈ $86.91K
-7.42pp
2013-12-31 23.92% ILA8.31 Million
≈ $22.29K
ILA34.76 Million
≈ $93.18K
-3.34pp
2012-12-31 27.25% ILA11.77 Million
≈ $31.55K
ILA43.19 Million
≈ $115.78K
-8.32pp
2011-12-31 35.57% ILA15.51 Million
≈ $41.57K
ILA43.60 Million
≈ $116.88K
-0.77pp
2010-12-31 36.34% ILA22.18 Million
≈ $59.47K
ILA61.05 Million
≈ $163.66K
-3.31pp
2009-12-31 39.65% ILA22.20 Million
≈ $59.52K
ILA55.99 Million
≈ $150.11K
+38.43pp
2008-12-31 1.22% ILA258.00K
≈ $691.69
ILA21.11 Million
≈ $56.58K
--
pp = percentage points

About Hadasit Bio

TA:HDST Israel Biotechnology & Medical Research
Market Cap
$2.16 Million
ILA803.92 Million ILA
Market Cap Rank
#29806 Global
#438 in Israel
Share Price
ILA72.50
Change (1 day)
+0.00%
52-Week Range
ILA28.10 - ILA83.00
All Time High
ILA2847.77
About

HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more